Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation

Robert M. Cardinale, Rupert K. Schmidt-Ullrich, Stanley H Benedict, Robert D. Zwicker, Daniel C. Han, William C. Broaddus

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

The purpose of this pilot study was to determine the feasibility and toxicities of an accelerated treatment program by using a concomitant stereotactic radiotherapy boost given weekly during a course of standard external-beam irradiation (EBXRT) in patients with malignant gliomas. Twelve patients underwent biopsy or subtotal resection of a malignant glioma and were enrolled on the protocol, which delivered 44 Gy-EBXRT and a 12-Gy stereotactic radiotherapy boost given on 3 consecutive weeks of treatment for a total dose of 80 Gy over 33 days. Three patients with anaplastic astrocytoma and nine patients with glioblastoma multiforme had median survival times of 33 months and 16 months, respectively. All of the tumor recurrences were within or were closely adjacent to the region of high-dose irradiation. None of the patients required a treatment break, and there were no acute complications. Two patients developed seizures in the follow-up period, and four patients were diagnosed with radionecrosis at the time of the second operation. The treatment program was found to be feasible and was well tolerated, and it resulted in a rate of late complications similar to those of radiosurgery or interstitial brachytherapy.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalRadiation Oncology Investigations
Volume6
Issue number4
DOIs
StatePublished - 1998
Externally publishedYes

Keywords

  • Astrocytoma
  • Glioblastoma
  • Radiosurgery
  • Stereotactic

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Fingerprint Dive into the research topics of 'Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation'. Together they form a unique fingerprint.

  • Cite this